Antibiotic Selection for Cellulitis
For typical non-purulent cellulitis without systemic signs, treat with an antibiotic targeting β-hemolytic streptococci alone—specifically penicillin, amoxicillin, or cephalexin—and do NOT routinely cover MRSA. 1, 2
Treatment Algorithm Based on Clinical Presentation
Mild Non-Purulent Cellulitis (Outpatient)
- First-line options targeting streptococci:
- Penicillin VK 250-500 mg every 6 hours PO
- Cephalexin (dose per guidelines)
- Amoxicillin
- Duration: 5 days minimum, extend if not improving 1
- MRSA coverage is NOT needed for typical cases 2
The evidence strongly supports that β-hemolytic streptococci cause the vast majority of non-purulent cellulitis, and empirical MRSA coverage adds no benefit despite high community MRSA prevalence 3, 4, 5, 6.
Moderate Non-Purulent Cellulitis with Systemic Signs
- Consider adding MSSA coverage (weak recommendation) 1
- Options: Cefazolin 1 g IV every 8 hours or nafcillin 1-2 g IV every 4-6 hours
- Still primarily streptococcal—many clinicians may choose streptococcal coverage alone
Severe Non-Purulent Cellulitis or High MRSA Risk
Add MRSA coverage ONLY if:
- Penetrating trauma
- Known MRSA colonization
- Injection drug use
- SIRS/sepsis present
- Failed β-lactam therapy 1, 2
MRSA-active options for severe cases:
- IV: Vancomycin (first-line), linezolid 600 mg IV/PO twice daily, daptomycin 4 mg/kg IV daily, telavancin 10 mg/kg IV daily 2
- Oral: Clindamycin, TMP-SMX, doxycycline/minocycline, or linezolid 2
Purulent Cellulitis (with drainage/exudate, no drainable abscess)
- Empirical MRSA coverage IS required 2
- Streptococcal coverage is likely unnecessary 2
- Oral options: Clindamycin (covers both if needed), TMP-SMX, tetracyclines, or linezolid
- Duration: 5-10 days 2
Dual Coverage Strategy (When Both Pathogens Suspected)
If you must cover both streptococci and MRSA:
Hospitalized Patients with Complicated SSTI
- Vancomycin remains first-line IV option 2
- Alternative IV agents: linezolid, daptomycin, telavancin, clindamycin
- For non-purulent cellulitis in hospital: Consider cefazolin initially, switch to MRSA coverage only if no clinical response 2
- Duration: 7-14 days based on response 2
Pediatric Considerations
- Same principles apply: non-purulent cellulitis rarely needs MRSA coverage
- Avoid tetracyclines under age 8 2
- Hospitalized children: Vancomycin preferred; clindamycin 10-13 mg/kg/dose IV every 6-8 hours if local resistance <10% 2
- Linezolid dosing: 10 mg/kg every 8 hours if <12 years; 600 mg twice daily if ≥12 years 2
Critical Pitfalls to Avoid
Do not reflexively cover MRSA just because community prevalence is high—multiple studies show no benefit in non-purulent cellulitis 3, 4, 5, 6. This leads to unnecessary broad-spectrum use, increased costs, and resistance.
Do not use rifampin as monotherapy or adjunctive therapy for cellulitis 2.
Do not obtain routine cultures in uncomplicated cellulitis—they have poor yield 1. Reserve cultures for immunocompromised patients, malignancy, neutropenia, immersion injuries, animal bites, or treatment failure 1.
Do not forget adjunctive measures: Elevate affected limb, examine interdigital toe spaces for fungal infection (common predisposing factor for lower extremity cellulitis), and address underlying edema or skin conditions 1.
When to Hospitalize
- SIRS criteria present
- Altered mental status or hemodynamic instability
- Concern for deeper/necrotizing infection
- Severe immunocompromise
- Outpatient treatment failure 1
Nuance in the Evidence
The 2014 IDSA guidelines 1 are more recent than the 2011 MRSA guidelines [2-2] and provide the most comprehensive framework. Both consistently emphasize that non-purulent cellulitis is predominantly streptococcal and does not require routine MRSA coverage. Recent research 3, 4, 5, 6 reinforces this, showing equivalent cure rates with penicillin/cephalexin versus broader agents. The key distinction is purulent versus non-purulent presentation—purulent forms warrant MRSA coverage, non-purulent forms do not unless specific risk factors exist.